Systemic delivery of tenofovir alafenamide using dissolving and implantable microneedle patches

Paredes, Alejandro J.; Volpe‐Zanutto, Fabiana; Vora, Lalitkumar K.; Tekko, Ismaiel; Permana, Andi Dian; Picco, Camila J.; McCarthy, Helen; Donnelly, Ryan F.

doi:10.1016/j.mtbio.2022.100217

Cited by 22 publications

(13 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The in vitro release profiles of coarse CUR, PM, CUR NCs and Egel-20-NCs were assessed using a dialysis membrane model according to a previously described methodology [ 27 , 28 ]. The release media consisted of 100 mL of 2% w/v Tween® 80 in buffer saliva pH 6.4 containing 0.5% w/v of ascorbic acid to prevent drug degradation [ 29 ].…”

Section: Methodsmentioning

confidence: 99%

Bioadhesive eutectogels supporting drug nanocrystals for long-acting delivery to mucosal tissues

Bianchi

Zhang

Catlin

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Bioadhesive eutectogels supporting drug nanocrystals for long-acting delivery to mucosal tissues

Bianchi

Zhang

Catlin

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

“…The release study performed using dialysis methods demonstrated the relatively fast drug release in both the formulations. The in vivo studies in rats showed rapid metabolization of the TAF into tenofovir, along with quick elimination of the metabolite from the blood plasma [ 224 ].…”

Section: Applications Of Mnsmentioning

confidence: 99%

Recent Advancements in Microneedle Technology for Multifaceted Biomedical Applications

Kulkarni¹,

Damiri

Rojekar

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Microneedle (MNs) technology is a recent advancement in biomedical science across the globe. The current limitations of drug delivery, like poor absorption, low bioavailability, inadequate skin permeation, and poor biodistribution, can be overcome by MN-based drug delivery. Nanotechnology made significant changes in fabrication techniques for microneedles (MNs) and design shifted from conventional to novel, using various types of natural and synthetic materials and their combinations. Nowadays, MNs technology has gained popularity worldwide in biomedical research and drug delivery technology due to its multifaceted and broad-spectrum applications. This review broadly discusses MN’s types, fabrication methods, composition, characterization, applications, recent advancements, and global intellectual scenarios.

show abstract

“…Donnelly et al in collaboration with PATH, developed a dissolving MAP containing LA nanosuspension of RPV [ 129 ]. Most recently, they have also developed a bilayer MAP loaded with CAB [ 130 ] and a dissolvable and implantable MAP loaded with TAF [ 131 ] for long-term HIV PrEP ( Figure 3c ). CONRAD in partnership with the University of Connecticut is further developing this technology for the delivery of bnAbs (manuscript submitted).…”

Section: Approaches To Improving Existing Arvs For La Hiv Preventionmentioning

confidence: 99%

“… (a) Design and mechanism of release of an ISFIs (Reproduced with permission from [ 9 ]) ; (b) The design of the gastric resident dosage forms consisting of an elastomeric core (grey) and six rigid arms loaded with a drug polymer matrix (multi-colored) (Reproduced with permission from [ 122 ]); (c) Schematics of intradermal administration of TAF using dissolving and implantable microarray patch (MAP) (Reproduced with permission from [ 131 ]). All the figures are reproduced under the terms and conditions of the Creative Commons Attribution (CC BY) license http://creativecommons.org/licenses/by/4.0/ ).…”

Section: Figurementioning

confidence: 99%

Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges

Agrahari

Anderson

Peet

et al. 2022

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Introduction: Poor or inconsistent adherence to daily oral pre-exposure prophylaxis (PrEP) has emerged as a key barrier to effective HIV prevention. The advent of potent long-acting (LA) antiretrovirals (ARVs) in conjunction with advances in controlled release technologies has enabled LA ARV drug delivery systems (DDS) capable of providing extended dosing intervals and overcome the challenge of suboptimal drug adherence with daily oral dosing. Areas covered: This review discusses the current state of the LA PrEP field, recent advances, and emerging technologies, including ARV prodrug modifications and new DDS. Technological challenges, knowledge gaps, preclinical testing considerations, and future directions important in the context of clinical translation and implementation of LA HIV PrEP are discussed. Expert opinion: The HIV prevention field is evolving faster than ever and the bar for developing next-generation LA HIV prevention options continues to rise. The requirements for viable LA PrEP products to be implemented in resource-limited settings are challenging, necessitating proactive consideration and product modifications during the design and testing of promising new candidates. If successfully translated, next-generation LA PrEP that are safe, affordable, highly effective, and accepted by both end-users and key stakeholders will offer significant potential to curb the HIV pandemic.

show abstract

Systemic delivery of tenofovir alafenamide using dissolving and implantable microneedle patches

Cited by 22 publications

References 50 publications

Bioadhesive eutectogels supporting drug nanocrystals for long-acting delivery to mucosal tissues

Bioadhesive eutectogels supporting drug nanocrystals for long-acting delivery to mucosal tissues

Recent Advancements in Microneedle Technology for Multifaceted Biomedical Applications

Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges

Contact Info

Product

Resources

About